PMID- 21131008
OWN - NLM
STAT- MEDLINE
DCOM- 20110617
LR  - 20220129
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
VI  - 301
IP  - 1-2
DP  - 2011 Feb 15
TI  - Non-radioactive serological diagnosis of myasthenia gravis and clinical features 
      of patients from Tianjin, China.
PG  - 71-6
LID - 10.1016/j.jns.2010.10.023 [doi]
AB  - PURPOSE: To establish non-radioactive assays for detection of antibodies (Abs) to 
      the acetylcholine receptor (AChR) and to muscle specific kinase (MuSK). To show 
      that the assays can be used in Tianjin for testing patients with MG. METHOD: AChR 
      and MuSK Abs in 51 Chinese MG patients' sera were tested in Oxford, UK, using the 
      conventional radioimmunoprecipitation assay (RIPA), a recently described 
      cell-based assay (CBA), and a new non-radioactive fluorescence 
      immunoprecipitation assay (FIPA) which can measure both AChR and MuSK antibodies 
      in one step. 102 MG sera were subsequently tested by CBA and FIPA in Tianjin, 
      China. Based on the different serological subgroups, the clinical features of 
      these 153 MG patients were analyzed. RESULTS: We first confirmed the sensitivity 
      and specificity of the assays in Oxford. There was good agreement between the 
      FIPA and the RIPA for AChR Abs (r(2) = 0.6; p < 0.0001) with 80% positivity in the 
      RIPA and 76% in the FIPA. Two patients were positive for MuSK Abs (4% of total) 
      by both RIPA and FIPA assays. CBA was more sensitive for MuSK Abs, identifying an 
      additional 3 patients. In Tianjin, using the FIPA and CBA, 84/102 (82%) AChR Ab 
      positive patients and four MuSK Ab positive patients were identified. In the 
      whole group of 153 MG patients, there were no differences in clinical features 
      between different antibody subgroups. However, there were 30 patients with 
      thymomas (20%), of whom one had MuSK antibodies. Moreover, two patients with 
      purely ocular MG also had MuSK antibodies. CONCLUSIONS: Both the FIPA and CBA 
      were established in China and should prove useful for diagnostic testing. 
      Including the CBA for MuSK antibodies increased the number of MuSK-MG patients to 
      6% of the total, and 33% of the patients without AChR antibodies. The clinical 
      features were mainly relatively mild but thymic tumors were common.
CI  - Crown Copyright A(c) 2010. Published by Elsevier B.V. All rights reserved.
FAU - Yang, Li
AU  - Yang L
AD  - Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, 
      England, UK.
FAU - Maxwell, Susan
AU  - Maxwell S
FAU - Leite, M Isabel
AU  - Leite MI
FAU - Waters, Patrick
AU  - Waters P
FAU - Clover, Linda
AU  - Clover L
FAU - Fan, Xin
AU  - Fan X
FAU - Zhang, Daqi
AU  - Zhang D
FAU - Yang, Chunsheng
AU  - Yang C
FAU - Beeson, David
AU  - Beeson D
FAU - Vincent, Angela
AU  - Vincent A
LA  - eng
GR  - 084655/Wellcome Trust/United Kingdom
GR  - G0701521/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Validation Study
DEP - 20101204
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - 0 (Autoantibodies)
RN  - 0 (Fluorescent Dyes)
RN  - 0 (Receptors, Cholinergic)
RN  - 0 (enhanced green fluorescent protein)
RN  - 147336-22-9 (Green Fluorescent Proteins)
RN  - EC 2.7.10.1 (MUSK protein, human)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibody Specificity
MH  - Autoantibodies/*blood
MH  - Cells, Cultured
MH  - China/epidemiology
MH  - Female
MH  - Fluorescent Antibody Technique, Indirect
MH  - Fluorescent Dyes/analysis
MH  - Green Fluorescent Proteins/analysis
MH  - Humans
MH  - Immunoprecipitation/*methods
MH  - Male
MH  - Middle Aged
MH  - Myasthenia Gravis/*diagnosis/epidemiology/etiology/immunology
MH  - Radioimmunoprecipitation Assay
MH  - Receptor Protein-Tyrosine Kinases/*immunology
MH  - Receptors, Cholinergic/*immunology
MH  - Sensitivity and Specificity
MH  - Thymoma/complications
MH  - Thymus Neoplasms/complications
MH  - Young Adult
EDAT- 2010/12/07 06:00
MHDA- 2011/06/18 06:00
CRDT- 2010/12/07 06:00
PHST- 2010/02/28 00:00 [received]
PHST- 2010/10/20 00:00 [revised]
PHST- 2010/10/25 00:00 [accepted]
PHST- 2010/12/07 06:00 [entrez]
PHST- 2010/12/07 06:00 [pubmed]
PHST- 2011/06/18 06:00 [medline]
AID - S0022-510X(10)00538-1 [pii]
AID - 10.1016/j.jns.2010.10.023 [doi]
PST - ppublish
SO  - J Neurol Sci. 2011 Feb 15;301(1-2):71-6. doi: 10.1016/j.jns.2010.10.023. Epub 
      2010 Dec 4.